Advertisement

Hypertension

Chapter
  • 724 Downloads
Part of the Contemporary Cardiology book series (CONCARD)

Abstract

There are as many as 1 billion individuals with hypertension worldwide and physicians have only four recommended antihypertensive drugs to treat this varied population of patients. More than 50 million Americans have hypertension, and at ages 65–75 more than 60% of individuals have hypertension. The incidence is higher in African Americans.

Keywords

Diastolic Blood Pressure Calcium Antagonist Antihypertensive Agent Renal Artery Stenosis Resistant Hypertension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. 1.
    ALLH AT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–2997.CrossRefGoogle Scholar
  2. 2.
    Aram V, Chobanian MD, Bakris GL, et al. and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and the Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289:2560–2571.CrossRefGoogle Scholar
  3. 3.
    Bakris GL, Fonseca V, Katholi RE, et al. for the GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004;292:2227–2236.PubMedCrossRefGoogle Scholar
  4. 4.
    Bennet NE. Hypertension in the elderly. Lancet 1994;344:447.PubMedCrossRefGoogle Scholar
  5. 5.
    Black HR, Elliott WJ, Grandits G, et al., CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073–2082PubMedCrossRefGoogle Scholar
  6. 6.
    Carlberg B, Samuelsso O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684–1689.PubMedCrossRefGoogle Scholar
  7. 7.
    Cominacini L, Fratta Pasini A, Garbin U, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol 2003;42:1838–1844.PubMedCrossRefGoogle Scholar
  8. 8.
    Committee on Detection, Evaluation and Treatment of High Blood Pressure. The seventh report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNCV). Arch Intern Med 2003.Google Scholar
  9. 9.
    Crow RS, Prineas RJ, Routaharju P, et al. Relation between electrocardiography and echocardiography for left ventricular mass in mild systemic hypertension (Results from Treatment of Mild Hypertension Study). Am J Cardiol 1995;75:1233.PubMedCrossRefGoogle Scholar
  10. 10.
    Cunningham FG, Lindheimer MD. Current concepts: hypertension inpregnancy. N Engl J Med 1992;326:927.PubMedCrossRefGoogle Scholar
  11. 11.
    Dabaghi S. ACE inhibitors and pancreatitis. Ann Intern Med 1991;115:331.Google Scholar
  12. 12.
    Edelson JF, Weinstein MC, Tosteson ANA, et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990;263:408.CrossRefGoogle Scholar
  13. 13.
    Felson DT, Sloutskis D, Anderson JJ, et al. Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study. JAMA 1991;265:370.PubMedCrossRefGoogle Scholar
  14. 14.
    Franco V, Oparil S, Carretero OA. Hypertensive therapy: part II. Circulation 2004;109:3081–3088.PubMedCrossRefGoogle Scholar
  15. 15.
    Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326.PubMedGoogle Scholar
  16. 16.
    Giannoccaro PJ, Wallace GJ, Higginson LAJ, et al. Fatal angioedema associated with enalapril. Can J Cardiol 1989;5:335.PubMedGoogle Scholar
  17. 17.
    Hanson MW, Feldman JM, Beam CA, et al. Iodine 131-labeled metaiodobenzylguanidine scintigraphy and biochemical analyses in suspected pheochromocytoma. Arch Intern Med 1991;151:1397.PubMedCrossRefGoogle Scholar
  18. 18.
    Hartman RP, Kawashima A, King F. Evaluation of renal causes of hypertension Radiol Clin N Am 2003;41:909.PubMedCrossRefGoogle Scholar
  19. 19.
    Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003;107:1401–1406.PubMedCrossRefGoogle Scholar
  20. 20.
    Khan M Gabriel. Hypertension. In: Cardiac Drug Therapy. Sixth edition. Philadelphia: WB Saunders, 2003.Google Scholar
  21. 21.
    Lakshman MR, Reda DJ, Materson B J, et al, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Arch Intern Med 1999;159:551–558.PubMedCrossRefGoogle Scholar
  22. 22.
    Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 1995;333:201.PubMedCrossRefGoogle Scholar
  23. 23.
    Lunde H, Hedner T, Samuelsson O, et al. Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 1994;308:18.PubMedGoogle Scholar
  24. 24.
    Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000;283:1967–1975.Google Scholar
  25. 25.
    Materson BJ, Reda DJ, Cushman WC. Single drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914.PubMedCrossRefGoogle Scholar
  26. 26.
    Mattioli AV, Zennaro M, Bonatti S, et al. Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 2004;97(3):383–388.PubMedCrossRefGoogle Scholar
  27. 27.
    Nissen SE, Tuzcu EM, Libby P, et al. for the CAMELOT Investigators. Effect of Antihypertensive Agents on Cardiovascular Events in Patients with Coronary Disease and Normal Blood Pressure: The CAMELOT Study: a randomized controlled trial. JAMA 2004;292:2217–2225.PubMedCrossRefGoogle Scholar
  28. 28.
    Panacek EA, Bednarxzyk EM, Dunbar LM, et al. Randomized prospective trial of fenoldopam versus sodium nitroprusside in the treatment of acute severe hypertension. Acad Emerg Med 1995;2:959.PubMedCrossRefGoogle Scholar
  29. 29.
    Parks WJ, Thang DM, Plauth WH, et al. Incidence of aneurysm formation after dacron patch aortoplasty repair for coarctation of the aorta: long-term results and assessment utilizing magnetic resonance angiography with three-dimensional surface rendering. J Am Coll Cardiol 1995;26:266.PubMedCrossRefGoogle Scholar
  30. 30.
    Pearson AC, Pasierski T, Labovitz AJ. Left ventricular hypertrophy: diagnosis, prognosis and management. Am Heart J 1991;121:148.PubMedCrossRefGoogle Scholar
  31. 31.
    Pepine CJ. What is the optimal blood pressure and drug therapy for patients with coronary artery disease? JAMA 2004;292:2271–2273.PubMedCrossRefGoogle Scholar
  32. 32.
    Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831–1838.PubMedCrossRefGoogle Scholar
  33. 33.
    Salathe M, Weiss P, Ritz R. Rapid reversal of heart failure in a patient with pheochromocytoma and catecholamine-induced cardiomyopathy who was treated with captopril. Br Heart J 1992;68:527.PubMedCrossRefGoogle Scholar
  34. 34.
    SHEP Cooperative Study Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Programs (SHEP). JAMA 1991;265:3255.CrossRefGoogle Scholar
  35. 35.
    Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting enzyme inhibition. JAMA 1988;260:967.PubMedCrossRefGoogle Scholar
  36. 36.
    Szlachcic J, Tubau JF, O’Kelly B, et al. What is the role of silent coronary artery disease and left ventricular hypertrophy in the genesis of ventricular arrhythmias in men with essential hypertension? J Am Coll Cardiol 1992;19:803.PubMedCrossRefGoogle Scholar
  37. 37.
    The Treatment of Mild Hypertension Research Group. The treatment of mild hypertension study. A randomized, placebo-controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch Intern Med 1991;151:1413.CrossRefGoogle Scholar
  38. 38.
    UK prospective Diabetes study group. Efficacy of atenolol and captopril in reducing risk of microvascular and macrovascular complications in Type II diabetes: UKPDS. BMJ 1998;317:713.Google Scholar
  39. 39.
    Wassertheil-Smoller S, Blaufox D, Oberman A, et al. Effect of anti-hypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med 1991;114:613.PubMedGoogle Scholar
  40. 40.
    Wilkstrand J, Warnold I, Tuomilhto J, et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension 1991;17:579.Google Scholar
  41. 41.
    Wood SM, Mann RD, Rawlins MD. Angioedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J 1987;294:91.Google Scholar
  42. 42.
    Yusuf S. Calcium antagonists in coronary artery disease and hypertension: time for reevaluation? Circulation 1995;92:1079.PubMedGoogle Scholar
  43. 43.
    Yusuf S, Gerstein H, Hoogwerf B, et al, for the HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001;286:1882–1885.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Personalised recommendations